sc-002

SC-002 is a bioengineered, DLL3-directed antibody-drug conjugate (ADC) developed for the treatment of cancers such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). It consists of a monoclonal antibody targeting delta-like ligand 3 (DLL3), conjugated via a plasma-stable valine-alanine dipeptide linker to the cytotoxic pyrrolobenzodiazepine (PBD) dimer warhead, SC-DR002. Upon binding to DLL3-expressing tumor cells, SC-002 is internalized and releases its cytotoxic payload through cathepsin-mediated proteolysis within endosomes. The drug was evaluated in phase 1 clinical trials for relapsed or refractory SCLC and LCNEC but demonstrated limited efficacy and notable systemic toxicity. Development has since been discontinued[1][4][5][7].